6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-b-D-ribofuranosyl)purine
Modify Date: 2024-04-03 21:19:08
6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-b-D-ribofuranosyl)purine structure
|
Common Name | 6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-b-D-ribofuranosyl)purine | ||
|---|---|---|---|---|
| CAS Number | 161923-50-8 | Molecular Weight | 428.78 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H17ClN4O8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-b-D-ribofuranosyl)purine6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. |
| Name | 6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-b-D-ribofuranosyl)purine |
|---|---|
| Synonym | More Synonyms |
| Description | 6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C16H17ClN4O8 |
|---|---|
| Molecular Weight | 428.78 |
| Exact Mass | 428.07300 |
| PSA | 151.96000 |
| LogP | 0.50920 |
| Index of Refraction | 1.678 |
|
~97%
6-Chloro-2-hydr... CAS#:161923-50-8 |
| Literature: Moorman, Allan R. Patent: US2003/199686 A1, 2003 ; Location in patent: Page/Page column 6 ; |
| Precursor 1 | |
|---|---|
| DownStream 1 | |
CAS#:1818-71-9| 6-chloropyrazine-2-ylhydrazine |
| 2-chloro-6-hydrazinopyridazine |
| 2-Hydrazino-6-chlorpyrazin |
| 2-Chloro-6-hydrazinylpyrazine |
| 2',3',5'-triacetyl-6-chloroguanosine |
| 6-chloro-2-hydrazinopyrazine |
| 2-chloro-6-hydrazino-pyrazine |